Article thumbnail

Mesenchymal Stem Cells Exhibit Firm Adhesion, Crawling, Spreading and Transmigration across Aortic Endothelial Cells: Effects of Chemokines and Shear

By Giselle Chamberlain, Helen Smith, G. Ed Rainger and Jim Middleton


Mesenchymal stem cells (MSCs) have anti-inflammatory and immunosuppressive properties and may be useful in the therapy of diseases such as arteriosclerosis. MSCs have some ability to traffic into inflamed tissues, however to exploit this therapeutically their migratory mechanisms need to be elucidated. This study examines the interaction of murine MSCs (mMSCs) with, and their migration across, murine aortic endothelial cells (MAECs), and the effects of chemokines and shear stress. The interaction of mMSCs with MAECs was examined under physiological flow conditions. mMSCs showed lack of interaction with MAECs under continuous flow. However, when the flow was stopped (for 10min) and then started, mMSCs adhered and crawled on the endothelial surface, extending fine microvillous processes (filopodia). They then spread extending pseudopodia in multiple directions. CXCL9 significantly enhanced the percentage of mMSCs adhering, crawling and spreading and shear forces markedly stimulated crawling and spreading. CXCL9, CXCL16, CCL20 and CCL25 significantly enhanced transendothelial migration across MAECs. The transmigrated mMSCs had down-regulated receptors CXCR3, CXCR6, CCR6 and CCR9. This study furthers the knowledge of MSC transendothelial migration and the effects of chemokines and shear stress which is of relevance to inflammatory diseases such as arteriosclerosis

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential.
  2. (2005). Agonist-induced endocytosis of CC chemokine receptor 5 is clathrin dependent.
  3. (2005). Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets.
  4. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide.
  5. (2008). Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
  6. (2000). CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand.
  7. (2008). Cells on the run: shear-regulated integrin activation in leukocyte rolling and arrest on endothelial cells.
  8. (2008). Characterization of key mechanisms in transmigration and invasion of mesenchymal stem cells.
  9. (2008). Chemokines in atherosclerosis: an update.
  10. (2007). Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing.
  11. (2000). Differential MMP and TIMP production by human marrow and peripheral blood CD34(+) cells in response to chemokines.
  12. (1994). Dynamics of neutrophil rolling over stimulated endothelium in vitro.
  13. (2008). Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to bone.
  14. (2007). Functional analysis of an established mouse vascular endothelial cell line.
  15. (2007). Getting to the site of inflammation: the leukocyte adhesion cascade updated.
  16. (2007). Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors.
  17. (2007). Human mesenchymal stem cells constitutively express chemokines and chemokine receptors that can be upregulated by cytokines, IFN-beta, and Copaxone.
  18. (2006). Importance of force linkage in mechanochemistry of adhesion receptors.
  19. (2007). In vivo tracking of stem cells in brain and spinal cord injury.
  20. (1990). Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene.
  21. (2006). Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade.
  22. (2006). Intravenous administration of glial cell line-derived neurotrophic factor genemodified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat.
  23. (2006). Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties.
  24. (1999). Kinetics of the different steps during neutrophil migration through cultured endothelial monolayers treated with tumour necrosis factor-alpha.
  25. Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details.
  26. (2007). Leukocyte membrane ‘‘expansion’’: a central mechanism for leukocyte extravasation.
  27. (2004). Locomotion of monocytes on endothelium is a critical step during extravasation.
  28. (2009). Lymphocyte crawling and transendothelial migration require chemokine triggering of high-affinity LFA-1 integrin.
  29. (2006). Mesenchymal stem cell adhesion to cardiac microvascular endothelium: activators and mechanisms.
  30. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy.
  31. (2008). Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type.
  32. (2006). Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells.
  33. (2006). Mesenchymal stem cells increase self-renewal of small intestinal epithelium and accelerate structural recovery after radiation injury. Adv Exp Med Biol 585:
  34. (2006). Mesenchymal stem cells transmigrate over the endothelial barrier.
  35. (2007). Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment.
  36. (2001). Mesenchymal stem cells.
  37. (2008). Molecular trafficking mechanisms of multipotent mesenchymal stem cells derived from human bone marrow and placenta.
  38. (2008). Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human.
  39. (2009). Myocardium-targeted transplantation of mesenchymal stem cells by diagnostic ultrasound-mediated microbubble destruction improves cardiac function in myocardial infarction of New Zealand rabbits.
  40. (2004). Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction.
  41. (2000). Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium.
  42. (2007). Potential risks of bone marrow cell transplantation into infarcted hearts.
  43. (2010). Recent developments and complexities in neutrophil transmigration.
  44. (2007). Successful treatment of refractory tibial non-union using calcium sulphate and bone marrow stromal cell transplantation.
  45. (2003). Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.
  46. (2008). Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance.
  47. (2007). The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities.
  48. (1993). The Peyer’s patch high endothelial receptor for lymphocytes, the mucosal vascular addressin, is induced on a murine endothelial cell line by tumor necrosis factor-alpha and IL-1.
  49. (2010). Therapeutic targeting of chemokine interactions in atherosclerosis.
  50. (2007). Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.